Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0311120080490020217
Yonsei Medical Journal
2008 Volume.49 No. 2 p.217 ~ p.223
The Effect of Lowering the Threshold for Diagnosis of Impaired Fasting Glucose
Kim So-Hun

Lee Hoon-Jae
Hong Seong-Bin
Nam Moon-Suk
Kim Eun-Joo
Kim Yong-Seong
Lee Seung-Hee
Shim Wan-Sub
Park Shin-Goo
Kim Eun-A
Lim Jong-Whan
Abstract
Purpose: The aim of this study was to evaluate the effect of lowering the fasting plasma glucose (FPG) criteria for impaired fasting glucose (IFG) on the prevalence of IFG and the risk for the development of diabetes associated with IFG in Koreans.

Materials and Methods: A total of 7,211 subjects who had normal glucose tolerance (NGT) or IFG were recruited. Subjects were evaluated at baseline and after two years follow up. Clinical data including total cholesterol, FPG and blood pressure were examined.

Results: Lowering the criteria for IFG from 6.1mmol/L (110mg/dL) to 5.6mmol/L (100mg/dL) increased the prevalence of IFG from 6.6% (494 subjects) to 24.4% (1829 subjects). After the 2 years follow up period, 91 subjects (1.3%) developed diabetes. Twenty one (0.3%) subjects developed diabetes among 5,382 NGT subjects and 70 (3.8%) subjects developed diabetes among 1,829 IFG (5.6-7.0mmol/L) subjects. Lowering the IFG threshold from 6.1mmol/L to 5.6mmol/L resulted in a 18.4% decrease in specificity and 23.9% increase in sensitivity for predicting diabetes. The baseline FPG for predicting the development of diabetes after 2 years at a point on the receiver operating characteristic curve that was closest to the ideal 100% sensitivity and 100% specificity was 5.7mmol/L (103mg/dL).

Conclusion: Lowering the FPG criterion of IFG should have benefits in predicting new onset type 2 diabetes mellitus in Koreans. The economic and health benefits of applying the new IFG criteria should be evaluated in future studies.
KEYWORD
Impaired fasting glucose, normal glucose tolerance, type 2 diabetes mellitus
FullTexts / Linksout information
  
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed